Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Subscribe To Our Newsletter & Stay Updated
